medigraphic.com
ISSN 2007-2783 (Print)
Órgano Oficial del Instituto Científico Pfizer

2015, Number 3

<< Back Next >>

Residente 2015; 10 (3)

Trombocitopenia inmune primaria

García-Reyes B, Espinosa-Valdespino L, Nava-Zavala AH, Rubio-Jurado B

Language: Spanish
References: 29
Page: 154-165
PDF size: 255.10 Kb.


ABSTRACT

Primary immune thrombocytopenia is caused by excessive platelet destruction by autoantibodies directed against platelet membrane antigens as well as a deficient production by the megakaryocytes in the bone marrow. It can occur with or without bleeding. Thrombocytopenia is defined as a platelet count ‹ 100 x 109/L. The diagnosis is one of exclusion, in the absence of other diseases that may be associated with thrombocytopenia. The first-line of treatment are corticosteroids, but some patients do not respond to them and are candidates for second line therapy with splenectomy, rituximab or new therapies such as TPO-agonist for chronic TIP or refractory cases.


REFERENCES

  1. Sanz MA, Vicente-García V, Fernández A, López MF, Grande C, Jarque I et al. Diagnóstico, tratamiento y seguimiento de la trombocitopenia inmune primaria. Med Clínica. 2012; 138 (6): 261.e1-261.e17.

  2. Kistangari G, McCrae KR. Immune thrombocytopenia. Hematol Oncol Clin North Am. 2013; 27 (3): 495-520.

  3. Lo E, Deane S. Diagnosis and classification of immune-mediated thrombocytopenia. Autoimmun Rev. 2014; 13 (4-5): 577-583.

  4. Stasi R, Newland AC. ITP: a historical perspective. Br J Haematol. 2011; 153 (4): 437-450.

  5. Schoonen WM, Kucera G, Coalson J, Li L, Rutstein M, Mowat F et al. Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database. Br J Haematol. 2009; 145 (2): 235-244.

  6. Frederiksen H, Christiansen CF, Nørgaard M. Risk and prognosis of adult primary immune thrombocytopenia. Expert Rev Hematol. 2012; 5 (2): 219-228.

  7. Domínguez-García MV, Rodríguez-Moyado H. Cellular and biochemical mechanisms involved in physiopathogenesis of autoimmune thrombocytopenic purpura. Gac Med Mex. 2002; 138 (5): 461-472.

  8. Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009; 113 (11): 2386-2393.

  9. Neylon AJ, Saunders PW, Howard MR, Proctor SJ, Taylor PR; Northern Region Haematology Group. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol. 2003; 122 (6): 966-974.

  10. Rodeghiero F, Michel M, Gernsheimer T, Ruggeri M, Blanchette V, Bussel JB et al. Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group. Blood. 2013; 121 (14): 2596-2606.

  11. Stasi R, Amadori S, Osborn J, Newland AC, Provan D. Long-term outcome of otherwise healthy individuals with incidentally discovered borderline thrombocytopenia. PLoS Med. 2006; 3 (3): e24.

  12. Burrows RF, Kelton JG. Incidentally detected thrombocytopenia in healthy mothers and their infants. N Engl J Med. 1988; 319 (3): 142-145.

  13. McMillan R, Wang L, Tomer A, Nichol J, Pistillo J. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood. 2004; 103 (4): 1364-1369.

  14. Kashiwagi H, Tomiyama Y. Pathophysiology and management of primary immune thrombocytopenia. Int J Hematol. 2013; 98 (1): 24-33.

  15. Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009; 113 (20): 4834-4840.

  16. Zaja F, Battista ML, Pirrotta MT, Palmieri S, Montagna M, Vianelli N et al. Lower dose rituximab is active in adult patients with idiopathic thrombocytopenic purpura. Haematologica. 2008; 93 (6): 930-933.

  17. Vizcaíno G, Diez-Ewald M, Vizcaíno-Carruyo J. Treatment of chronic immune thrombocytopenic purpura. Looking for something better. Review. Investig Clínica. 2009; 50 (1): 95-108.

  18. Guía Práctica Clínica. Diagnóstico y tratamiento de púrpura trombocitopénica inmunológica. México: Secretaría de Salud; 2009. Disponible en: http://www.cenetec.salud.gob.mx/descargas/gpc/CatalogoMaestro/143_GPC_PURPURA_TROMBOCITOP/Imss_ER.pdf

  19. Cortelazzo S, Finazzi G, Buelli M, Molteni A, Viero P, Barbui T. High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura. Blood. 1991; 77 (1): 31-33.

  20. Mazzucconi MG, Fazi P, Bernasconi S, De Rossi G, Leone G, Gugliotta L et al. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood. 2007; 109 (4): 1401-1407.

  21. Cohen YC, Djulbegovic B, Shamai-Lubovitz O, Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med. 2000; 160 (11): 1630-1638.

  22. Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010; 115 (2): 168-186.

  23. Facultad de Medicina UNAM [Internet]. [citado el 27 de mayo de 2015]. Disponible en: http://www.facmed.unam.mx/bmnd/dirijo_gbc.php?bib_vv=22

  24. Goel R, Ness PM, Takemoto CM, Krishnamurti L, King KE, Tobian AAR. Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality. Blood. 2015; 125 (9): 1470-1476.

  25. Kalmadi S, Tiu R, Lowe C, Jin T, Kalaycio M. Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage. Cancer. 2006; 107 (1): 136-140.

  26. Neunert C, Lim W, Crowther M, Cohen A, Solberg L, Crowther MA. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011; 117 (16): 4190-4207.

  27. Lakshmanan S, Cuker A. Contemporary management of primary immune thrombocytopenia in adults. J Thromb Haemost. 2012; 10 (10): 1988-1998.

  28. Michel M. Immune thrombocytopenia nomenclature, consensus reports, and guidelines: what are the consequences for daily practice and clinical research? Semin Hematol. 2013; 50 Suppl 1: S50-S54.

  29. George JN. Sequence of treatments for adults with primary immune thrombocytopenia. Am J Hematol. 2012; 87 (S1): S12-S15.




2020     |     www.medigraphic.com